SecBot SecBot
SECBOTREPLAY Home › Report › BMRN

BMRN · Biogen completed its acquisition of Amicus Therapeutics for $4.8…

BIOMARIN PHARMACEUTICAL INC · 8-K filed Apr 27, 2026 at 08:45 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 27, 2026 at 08:45 ET

Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal through a $2.8 billion term loan package and previously issued notes. The acquisition adds Fabry and Pompe disease treatments to Biogen's portfolio, strengthening its rare disease focus.

  • Completed acquisition of Amicus Therapeutics for $4.8 billion in all-cash transaction
  • Acquired Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) treatments
  • Financed through $2.0 billion Term Loan B, $800 million Term Loan A, and $850 million 2034 Notes
  • Existing credit agreement was repaid and terminated

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access